AC
VRTX icon

Apogem Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Apogem Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,190
Closed -$216K – 213
2021
Q3 		$216K Sell
1,190
-905
-43% -$177K 0.14% 169
2021
Q2 		$422K Sell
2,095
-843
-29% -$176K 0.27% 123
2021
Q1 		$631K Buy
2,938
+1,146
+64% +$252K 0.43% 76
2020
Q4 		$424K Buy
+1,792
New +$411K 0.28% 107

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Apogem Capital's VRTX Position: Q4 2021 in Review

Apogem Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 1,190 shares — an estimated $216K sold.

Apogem Capital first reported a position in VRTX in Q4 2020 and held it in 4 quarters. The position peaked at $631K in Q1 2021. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Apogem Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Apogem Capital sold 1,190 Vertex Pharmaceuticals shares in Q4 2021, an estimated $216K.
  • Apogem Capital first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Apogem Capital's Vertex Pharmaceuticals position peaked at $631K in Q1 2021.
  • 1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.